Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04285866 | Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.(S-REAL) | completed | — | 245 | Fundación GECPOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT00263731 | Metabolomic Analysis of Lung Cancer | completed | — | 249 | University of LouisvilleOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT02995889 | FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer | completed | N/A | 64 | Rigshospitalet, DenmarkOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT02995902 | FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer(SIBES II) | completed | N/A | 13 | Rigshospitalet, DenmarkOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT05055947 | Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer | completed | — | 60 | Hunan Province Tumor HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05055999 | Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer | completed | — | 60 | Hunan Province Tumor HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT01780675 | Hippocampus Avoidance PCI vs PCI(HA-PCI) | completed | Phase 3 | 168 | The Netherlands Cancer InstituteOTHER | 2 | Jan 21, 2022 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT02394548 | Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer | completed | N/A | 27 | Massachusetts General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02273336 | Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer | completed | — | 40 | University of Southern CaliforniaOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer(ATLANTIS) | completed | Phase 3 | 613 | PharmaMarINDUSTRY | 20 | Oct 28, 2021 | clinicaltrials |
| NCT01797159 | Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer | completed | N/A | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT03911219 | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy(CHAPLIN) | completed | — | 154 | iOMEDICO AGINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT02948946 | Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | completed | — | 105 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT03086239 | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | completed | Phase 1 | 29 | AbbVieINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02397733 | Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) | completed | N/A | 150 | Grupo de Investigación Clínica en Oncología RadioterapiaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY) | completed | Phase 2 | 342 | AbbVieINDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT02701400 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 18 | Emory UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT00466466 | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 21, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT04451460 | Effect of Hyponatremia in Small Cell Lung Cancer | completed | — | 466 | Ankara City Hospital BilkentOTHER | 0 | Jun 30, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT00080015 | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 9 | IpsenINDUSTRY | 0 | Apr 29, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00921739 | Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies(ESIMRT) | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Apr 2, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2022source: clinicaltrials